Lupin Limited received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension. This product is a generic equivalent of AstraZeneca's Lokelma.
The drug treats hyperkalemia in adults. AstraZeneca's Lokelma generated estimated annual U.S. sales of USD 568 million. This revenue figure covers the twelve months ending June 2026.
Lupin also scheduled several upcoming analyst and institutional investor meetings. These sessions will occur throughout August and September 2026.